SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing heightened community attention as the company confirms its first shipments under a major Department of Defense supply contract. Investors are actively discussing the firm's strategic position as a sole domestic producer of critical minerals and speculating on potential stock momentum driven by institutional backing and the ramping of production capacity.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as investors react to a strong earnings beat, an upgraded full-year 2026 outlook, and a new multi-billion dollar share buyback program. The community is actively debating the company's long-term profitability shifts, its transition away from aggressive EV spending, and the potential impact of ongoing tariff headwinds on future margins.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is generating significant investor buzz following the unveiling of the Thunder autonomous VTOL platform, a dual-use aircraft developed with Anduril Industries that targets both defense and commercial markets. While the community is actively debating the company's long-term commercial scalability and the potential for a short squeeze, retail sentiment has surged to extremely bullish levels as investors anticipate upcoming announcements regarding commercial customers.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath Technologies is trending as investors capitalize on surging demand for its proprietary BlackDiamond infrared optics, which are increasingly replacing supply-constrained Chinese germanium in critical defense and aerospace applications. The stock is seeing heightened momentum and institutional interest driven by its pivotal role in the supply chains of major defense contractors and its recent inclusion in the Russell 2000 index.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is attracting significant attention as investors balance strong fundamental backlogs and multi-billion dollar contract wins against volatile headlines regarding defense budget priorities and potential regulatory oversight on executive compensation. The community remains deeply divided, with some actively scaling into positions on pullbacks to capture long-term aerospace growth, while others express frustration over intraday price swings and the sector's sensitivity to shifting policy narratives.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently experiencing significant volatility and intense debate among investors, primarily driven by speculation surrounding a potential strategic partnership with POSCO and the impact of recent government defense contracts for specialized steel. While some community members remain skeptical of management and bearish on the stock due to debt levels and historical performance, others see strong upside potential tied to infrastructure spending and data center demand for electrical steel.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing downward price pressure despite reporting strong Q1 revenue growth and record user adoption, as investors react cautiously to increased credit provisions and mixed margins. The community remains divided, with many long-term holders viewing the pullback as an accumulation opportunity while others focus on rising delinquency concerns.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the recent U.S. commercial launch of NEREUS for motion sickness while debating the company's prospects for a potential buyout by major pharmaceutical players like Eli Lilly or Novo Nordisk. The community remains focused on the firm's strategic push into GLP-1 adjunct treatments and active pipeline developments, even as participants express frustration over persistent price volatility and the company's confrontational regulatory strategy.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is seeing intense volatility as investors weigh strong systems integration growth against the expiration of procurement-heavy revenue cycles and broader concerns over customer concentration. The community remains deeply divided, with bulls pointing to long-term AI infrastructure potential and institutional ownership, while bears focus on declining year-over-year revenue trends and concerns regarding executive share sales.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community debate over the potential impact of the Clarity Act and ongoing market volatility. While some investors are accumulating in anticipation of regulatory breakthroughs, others remain skeptical, pointing to the coin's stagnant price action and criticizing the project's long-term utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.read more...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.read more...

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.341
Prev Close	$0.3559
Open	$0.355
Dividend Yield	0.00%
50-Day Moving Average	$0.4264
Beta	0.74
Avg. Volume	1.51M
PE Ratio	-0.02

52-Week High	$2.29
52-Week Low	$0.261
Market Capitalization	$15.78M
EPS (Annual)	-$6.25
Price to Book	1.58
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GTBPGT Biopharma Inc

Latest GTBP News